Vardulaki K A, Walker N M, Couto E, Day N E, Thompson S G, Ashton H A, Scott R A P
Medical Research Council Biostatistics Unit, Institute of Public Health and Strangeways Research Laboratory, Cambridge, UK.
Br J Surg. 2002 Jul;89(7):861-4. doi: 10.1046/j.1365-2168.2002.02133.x.
The study was an update at 10 years of a randomized trial of the efficacy of screening for abdominal aortic aneurysm (AAA). The extent of benefit, feasibility and compliance were examined, and reasons why this intervention may fail a proportion of those screened were identified.
A total of 6058 men aged 65 years and over were randomized to a group invited to attend ultrasonographic screening or to a control group. The mortality rate from AAA in the two arms of the trial was compared using a Poisson model. Analyses were by intention to treat.
There was a 21 per cent reduction in mortality rate from AAA over the 10-year follow-up (relative risk 0.79 (95 per cent confidence interval 0.53 to 1.40)). The observed relative mortality reduction peaked at 4 years with a 52 per cent reduction in the study group. Eighteen of 24 AAA deaths in the study group were among those who did not attend the first screen, or failed to comply with the follow-up protocol.
A greater awareness of the benefits of full participation in a screening programme could provide a larger and sustained mortality reduction.
本研究是一项针对腹主动脉瘤(AAA)筛查疗效的随机试验的10年更新研究。研究考察了获益程度、可行性和依从性,并确定了这种干预措施可能导致部分筛查对象未获成功的原因。
总共6058名65岁及以上男性被随机分为受邀参加超声筛查组或对照组。使用泊松模型比较试验两组中腹主动脉瘤的死亡率。分析采用意向性分析。
在10年随访期间,腹主动脉瘤死亡率降低了21%(相对风险0.79(95%置信区间0.53至1.40))。观察到的相对死亡率降低在4年时达到峰值,研究组降低了52%。研究组24例腹主动脉瘤死亡病例中有18例发生在未参加首次筛查或未遵守随访方案的人群中。
更充分认识到全面参与筛查计划的益处,可能会带来更大且持续的死亡率降低。